Discontinued — last reported Q3 '23
Intel Interest Paid increased by 630.6% to $642.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $611.00M to $642.00M. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $122.00M | -$12.00M | $274.00M | $177.00M | $37.00M | $101.00M | $144.00M | $313.00M | $80.00M | $575.00M | $540.00M | -$52.00M | $611.00M | $635.00M | -$121.00M | $642.00M |
| QoQ Change | — | -109.8% | >999% | -35.4% | -79.1% | +173.0% | +42.6% | +117.4% | -74.4% | +618.8% | -6.1% | -109.6% | >999% | +3.9% | -119.1% | +630.6% |
| YoY Change | — | — | — | — | -69.7% | +941.7% | -47.4% | +76.8% | +116.2% | +469.3% | +72.5% | -165.0% | +6.3% | +17.6% | -132.7% | +5.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.